Access DB# 118026

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: C. Delacroix-M Examiner #: 71100 Date: 10-6-05

Art Unit: 1614 Phone Number 82-0572 Serial Number: 09/700,165

Mail Box and Bldg/Room Location: Results Format Preferred (circle): PAPER DISK E-MAIL

43C70 43A78

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): please see attached

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

please search the method of claim 1, specifically searching the compound of Formula(I) for use in treating pain.

neuropathic pain
cancer pain
post-operative pain
herpetic pain
neuralgia pain
analgesia, anti-nociceptive

Key substituents in Formula(I) are highlighted.

Thanks
CDM

compound of formula(I) is a Bombesin Receptor Antagonist

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Beverly e2523	NA Sequence (#)	STN i
Searcher Phone #:	AA Sequence (#)	Dialog
Searcher Location:	Structure (#)	Questel/Orbit
Date Searcher Picked Up:	Bibliographic	Dr.Link
Date Completed:	Litigation	Lexis/Nexis
Searcher Prep & Review Time:	Fulltext	Sequence Systems
Clerical Prep Time:	Patent Family	WWW/Internet
Online Time:	Other	Other (specify)

FTO-1590 (8-01)

Delacroix-M.
09/700165

FILE 'REGISTRY' ENTERED AT 15:27:04 ON 11 OCT 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 OCT 2005 HIGHEST RN 864908-12-3
DICTIONARY FILE UPDATES: 10 OCT 2005 HIGHEST RN 864908-12-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

L1 STR



REP G1=(0-1) C
REP G2=(0-1) CH2
VAR G3=H/AK
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L2 (468) SEA FILE=REGISTRY SSS FUL L1
L3 STR



REP G1=(0-1) C
REP G2=(0-1) CH2
VAR G3=H/16
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS LOC AT 16
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L4 414 SEA FILE=REGISTRY SUB=L2 SSS FUL L3

100.0% PROCESSED 468 ITERATIONS 414 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 15:27:04 ON 11 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Oct 2005 VOL 143 ISS 16
FILE LAST UPDATED: 10 Oct 2005 (20051010/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L5 77 SEA ABB=ON PLU=ON L4

L6 9 SEA ABB=ON PLU=ON L5 AND (PAIN OR PHYSICAL?(3A)SUFFER? OR ANALGESI# OR ANTINOCICEPT? OR ANTI NOCICEPT? OR ACHE# OR ACHING)

E1 THROUGH E51 ASSIGNED

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:429408 CAPLUS
DOCUMENT NUMBER: 142:482316
TITLE: Preparation of amino acids derivatives as Glyt2 modulators, especially antagonists, for treating central nervous system conditions
INVENTOR(S): Barclay, Tristin K.; Santillan, Alejandro, Jr.; Tang, Liu Y.; Venkatesan, Hariharan; Wolin, Ronald L.
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N. V., Belg.
SOURCE: PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044810	A1	20050519	WO 2004-US36009	20041028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005119245	A1	20050602	US 2004-976067	20041028
PRIORITY APPLN. INFO.:			US 2003-515949P P	20031030

OTHER SOURCE(S): MARPAT 142:482316
GI



I



II

AB α-, β-, And γ-amino acid derivs. of formula I [wherein R1, R2 = independently H, alk(en)yl, cycloalkyl, benzyl; R1NR2 = (un)substituted saturated or partially unsatd. 4-7-membered heterocyclyl; R3 = H, alkyl optionally substituted with NH2; V = (CH2)n; n = 2-5; W = (CO)m; m = 0-1; Y = covalent bond, alkane-diyl, or cis or trans alkene-diyl, optionally substituted with 1 or 2 independently selected alkyl substituents; R4 = H, alkyl, Ph; R5 = alk(en)yl, Ph, thienyl, etc.; or R4CR5 = saturated or partially unsatd. 3-7-membered monocyclic carbocyclyl, optionally benzofused; R6 = H, alkyl; X = C:O, C:S, C:N-CN, C:CHNO2; Z = covalent bond, CH2; R7 = H, halo, alkyl; R8 = H, (un)substituted Ph, OPh, O-tetrahydronaphthyl, SOq-Ph, thienyl, pyridinyl; q = 0-2; or R7 and R8 together with the Ph to which they are attached form (un)substituted fluorenyl or tetrahydronaphthyl; and their stereoisomers, solvates, pharmaceutically acceptable salts and polymorphs] are disclosed as selective glycine transporter-2 (Glyt2) inhibitors, in particular antagonists, for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic **pain**. A 4-step synthesis is given for title compound II. II inhibited the uptake of [14C]-glycine in COS-7 cells transfected with human-Glyt2 with an IC50 = 11 nM.

IT **758698-57-6P**, (S)-2-[3-(Biphenyl-4-yl)ureido]-3-(pyridin-3-yl)-N-[3-(pyrrolidin-1-yl)propyl]propionamide **758698-59-8P**, (S)-2-[3-(Biphenyl-4-yl)ureido]-3-(pyridin-4-yl)-N-[3-(pyrrolidin-1-yl)propyl]propionamide **851968-37-1P**, (S)-2-[3-(4-Phenoxyphenyl)ureido]-N-[2-(pyrrolidin-1-yl)ethyl]-3-(thiazol-4-yl)propionamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of amino acids derivs. as Glyt2 modulators, especially antagonists, for treating central nervous system conditions)

RN 758698-57-6 CAPLUS

CN 3-Pyridinepropanamide, α-[[([1,1'-biphenyl]-4-ylamino)carbonyl]amino]-N-[3-(1-pyrrolidinyl)propyl]-, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 758698-59-8 CAPLUS
CN 4-Pyridinepropanamide, α-[[([1,1'-biphenyl]-4-ylamino)carbonyl]amino]-N-[3-(1-pyrrolidinyl)propyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851968-37-1 CAPLUS
CN 4-Thiazolepropanamide, α-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:487398 CAPLUS
DOCUMENT NUMBER: 137:41784
TITLE: Nonpeptide bombesin receptor antagonists for treatment and diagnosis of anxiety, panic disorders, cancers, ulcers, and other conditions
INVENTOR(S): Pinnock, Robert Denham; Pritchard, Martyn Clive
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Lucas, Brian Ronald
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049644	A1	20020627	WO 2000-GB4915	20001220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2432066	AA	20020627	CA 2000-2432066	20001220
AU 2001023816	A5	20020701	AU 2001-23816	20001220
EP 1343498	A1	20030917	EP 2000-987567	20001220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2000017393	A	20040203	BR 2000-17393	20001220
ZA 2003003723	A	20040514	ZA 2003-3723	20030514

PRIORITY APPLN. INFO.: WO 2000-GB4915 W 20001220

OTHER SOURCE(S): MARPAT 137:41784

AB New uses are disclosed for non-peptide bombesin receptor antagonists Ar[C(R1)(R8)]j(CH2)kN(R4)C(:O)N(R5)C(R7)(Ar1)C(:O)N(R6)(CH2)l[C(R2)(R9)]m(CH2)nR3 [j, k, m = 0, 1; l = 0-3; n = 0-2; Ar = (un)substituted Ph, (un)substituted pyridyl, (un)substituted pyrimidyl; R1 = H, C1-7 (un)branched (non)cyclic alkyl; R8 = H or forms C3-7 ring with R1; R2 = H, C1-8 (un)branched (non)cyclic alkyl which can also contain 1-2 O or N; R9 = H or forms ring with R2 or R2 and R9 together are carbonyl; Ar1 = Ar, indolyl, etc.; R4-R7 = H, lower alkyl, etc.; R3 = Ar, H, OH, NMe2, etc.] (I). Uses include the diagnosis, prevention, or treatment of anxiety, social phobia and panic disorders, pulmonary hypertension, lung repair and lung development disorders, prostate cancer, pancreatic cancer, hepatic porphyria, visceral **pain**, gastrointestinal secretory disturbances including duodenal ulcer and Helicobacter pylori infection and neuropathic **pain**. Also disclosed is a method for diagnosing or treating cancers using a radiolabeled I, as is a method for treating cancers using a conjugate of I with a cytotoxic agent.

IT **204067-01-6**

RL: DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonpeptide bombesin receptor antagonists for treatment and diagnosis of anxiety, panic disorders, cancers, ulcers, and other conditions)

RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:391535 CAPLUS

DOCUMENT NUMBER: 136:380143
TITLE: Treatment of sexual dysfunction using bombesin antagonist
INVENTOR(S): Gonzalez, Maria Isabel; Higginbottom, Michael; Pinnock, Robert Denham; Pritchard, Martyn Clive; Stock, Herman Thijs
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040022	A1	20020523	WO 2000-GB4380	20001117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2426521	AA	20020523	CA 2000-2426521	20001117
AU 2001014046	A5	20020527	AU 2001-14046	20001117
EP 1333829	A1	20030813	EP 2000-976165	20001117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2000017374	A	20030930	BR 2000-17374	20001117
JP 2004525864	T2	20040826	JP 2002-542395	20001117
CA 2429106	AA	20020523	CA 2001-2429106	20011114
WO 2002040008	A2	20020523	WO 2001-GB5018	20011114
WO 2002040008	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002023802	A5	20020527	AU 2002-23802	20011114
EP 1333824	A2	20030813	EP 2001-994552	20011114
EP 1333824	B1	20050907		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015364	A	20030923	BR 2001-15364	20011114
JP 2004522710	T2	20040729	JP 2002-542382	20011114
CN 1518445	A	20040804	CN 2001-821951	20011114
NZ 525415	A	20041126	NZ 2001-525415	20011114
AT 303804	E	20050915	AT 2001-994552	20011114
TW 220650	B1	20040901	TW 2001-90128451	20011116

ZA 2003003250	A	20040426	ZA 2003-3250		20030425
US 2004087561	A1	20040506	US 2003-416934		20031204
PRIORITY APPLN. INFO.:			WO 2000-GB4380	W	20001117
			GB 2001-9910	A	20010423
			GB 2001-11037	A	20010504
			WO 2001-GB5018	W	20011114

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. Preparation of compds. of the invention is included.

IT **204067-01-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bombesin antagonists for treatment of sexual dysfunction)

RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:391522 CAPLUS

DOCUMENT NUMBER: 136:395983

TITLE: Bombesin receptor antagonists, and combinations with other agents, for the treatment of sexual dysfunction

INVENTOR(S): Gonzalez, Maria Isabel; Stock, Herman Thijs; Pinnock, Robert Denham; Pritchard, Martyn Clive; Wayman, Christopher Peter; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Higginbottom, Michael

PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040008	A2	20020523	WO 2001-GB5018	20011114
WO 2002040008	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002040022	A1	20020523	WO 2000-GB4380	20001117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2429106	AA	20020523	CA 2001-2429106	20011114
AU 2002023802	A5	20020527	AU 2002-23802	20011114
EP 1333824	A2	20030813	EP 2001-994552	20011114
EP 1333824	B1	20050907		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015364	A	20030923	BR 2001-15364	20011114
JP 2004522710	T2	20040729	JP 2002-542382	20011114
NZ 525415	A	20041126	NZ 2001-525415	20011114
AT 303804	E	20050915	AT 2001-994552	20011114
US 2004087561	A1	20040506	US 2003-416934	20031204
PRIORITY APPLN. INFO.:			WO 2000-GB4380 W	20001117
			GB 2001-9910 A	20010423
			GB 2001-11037 A	20010504
			WO 2001-GB5018 W	20011114

OTHER SOURCE(S): MARPAT 136:395983

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compds., for example phosphodiesterase V

inhibitors, neutral endopeptidase inhibitors, and lasofoxifene. Preparation of compds. of the invention is described.

IT **204066-72-8 204066-73-9 204066-75-1 204066-76-2 204066-78-4 204066-79-5 204066-80-8 204066-82-0 204066-83-1 204066-84-2 204066-86-4 204066-87-5 204066-93-3 204066-95-5 204067-01-6 204067-38-9 428864-38-4 428864-39-5 428864-40-8 428864-41-9 428864-42-0 428864-43-1 428864-44-2 428864-45-3 428864-46-4 428864-47-5 428864-48-6 428864-49-7 428864-50-0 428864-51-1 428864-52-2 428864-53-3 428864-54-4 428864-55-5 428864-56-6 428864-57-7 428864-59-9**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

RN 204066-72-8 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2-cyclohexylethyl)-α-methyl- (9CI) (CA INDEX NAME)



RN 204066-73-9 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 204066-75-1 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 204066-76-2 CAPLUS
CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-78-4 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]methylamino]-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)



RN 204066-79-5 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)-α-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-80-8 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[[(1S)-1-(4-nitrophenyl)ethyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-82-0 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-83-1 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-α-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-84-2 CAPLUS
CN Benzoic acid, 4-[[[[(1S)-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[[1-(2-pyridinyl)cyclohexyl]methyl]amino]ethyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-86-4 CAPLUS
CN 1H-Indole-3-propanamide, N-[2,6-bis(1-methylethyl)phenyl]-α-[[[(2,2-dimethyl-1-phenylpropyl)amino]carbonyl]amino]-, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-87-5 CAPLUS
CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 204066-93-3 CAPLUS
CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (9CI) (CA INDEX NAME)



RN 204066-95-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (9CI) (CA INDEX NAME)



RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searcher : Shears 571-272-2528



RN 204066-87-5 CAPLUS
CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 204066-93-3 CAPLUS
CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (9CI) (CA INDEX NAME)



RN 204066-95-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (9CI) (CA INDEX NAME)



RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204067-38-9 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl- (9CI) (CA INDEX NAME)



RN 428864-38-4 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(4-aminophenyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 428864-39-5 CAPLUS
CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)-α-[[[[2-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-α-methyl- (9CI) (CA INDEX NAME)



RN 428864-40-8 CAPLUS
CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)-α-[[[(2,6-dichlorophenyl)amino]carbonyl]amino]-α-methyl- (9CI) (CA INDEX NAME)



RN 428864-41-9 CAPLUS
CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)-α-[[[(2,6-dimethoxyphenyl)amino]carbonyl]amino]-α-methyl- (9CI) (CA INDEX NAME)



RN 428864-42-0 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(dimethylamino)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)-α-methyl- (9CI) (CA INDEX NAME)



RN 428864-43-1 CAPLUS
CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)-α-[[[(2,2-dimethyl-1-phenylpropyl)amino]carbonyl]amino]-α-methyl- (9CI) (CA INDEX NAME)



RN 428864-44-2 CAPLUS
CN 1H-Indole-3-propanamide, N-[(2,2-dimethyl-4-phenyl-1,3-benzodioxol-5-yl)methyl]-α-methyl-α-[[[[(1-phenylcyclopentyl)methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 428864-45-3 CAPLUS
CN 1H-Indole-3-propanamide, N-[2,6-bis(1-methylethyl)phenyl]-α-[[[(2,2-dimethyl-1-phenylpropyl)amino]carbonyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 428864-46-4 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-benzodioxol-5-yl)-α-methyl- (9CI) (CA INDEX NAME)



RN 428864-47-5 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-cyclohexyl-α-methyl- (9CI) (CA INDEX NAME)



RN 428864-48-6 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 428864-49-7 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 428864-50-0 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 428864-51-1 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-(2-phenylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 428864-52-2 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,3-dihydro-1H-inden-1-yl)-α-methyl- (9CI) (CA INDEX NAME)



RN 428864-53-3 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[(1-hydroxycyclohexyl)methyl]-α-methyl- (9CI) (CA INDEX NAME)



RN 428864-54-4 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (9CI) (CA INDEX NAME)



RN 428864-55-5 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)- (9CI) (CA INDEX NAME)



RN 428864-56-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[(1-hydroxycyclohexyl)methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 428864-57-7 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(4-cyanophenyl)amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (9CI) (CA INDEX NAME)



RN 428864-59-9 CAPLUS
CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)-α-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:368981 CAPLUS
DOCUMENT NUMBER: 136:380137
TITLE: Bombesin receptor antagonists, and preparation thereof, for the treatment of sexual dysfunction
INVENTOR(S): Gonzalez, Maria Isabel; Pinnock, Robert Denham; Pritchard, Martyn Clive
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 72 pp., Cont.-in-part of U. S. Ser. No. 700,165.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002058606	A1	20020516	US 2001-759777		20010112
US 2002169101	A1	20021114	US 2001-999284		20011115
ZA 2003003249	A	20040623	ZA 2003-3249		20030425
PRIORITY APPLN. INFO.:			US 1999-133355P	P	19990510

Searcher : Shears 571-272-2528

WO 2000-GB1787	W	20000510
US 2000-700165	A2	20001109
US 2001-759777	A2	20010112
GB 2001-9910	A	20010423
GB 2001-11037	A	20010504

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females.

IT **204067-01-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bombesin receptor antagonists, preparation, and use for sexual dysfunction treatment, alone or with other agents)

RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	1999:487262 CAPLUS
DOCUMENT NUMBER:	131:116519
TITLE:	Preparation of N-(phenylcarbamoyl)-amino acid amides as calcitonin mimetics
INVENTOR(S):	Petrie, Charles; Mckernan, Patricia A.; Moore, Emma E.; Ostrech, John M.; Meyer, Jean-Philippe; Houghten, Richard A.; Pinella, Clemencia
PATENT ASSIGNEE(S):	Zymogenetics, Inc., USA; Trega Biosciences, Inc.
SOURCE:	PCT Int. Appl., 55 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937604	A2	19990729	WO 1999-US1151	19990120
WO 9937604	A3	19991014		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2284864	AA	19990729	CA 1999-2284864	19990120
AU 9922381	A1	19990809	AU 1999-22381	19990120
AU 743631	B2	20020131		
EP 975589	A2	20000202	EP 1999-902386	19990120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001501979	T2	20010213	JP 1999-538414	19990120
US 6221913	B1	20010424	US 1999-233893	19990120
US 6255351	B1	20010703	US 1999-410115	19990930
US 6391917	B1	20020521	US 2001-838726	20010419

PRIORITY APPLN. INFO.:	US 1998-72987P	P	19980121
	US 1999-233893	A3	19990120
	WO 1999-US1151	W	19990120
	US 1999-410115	A3	19990930

OTHER SOURCE(S): MARPAT 131:116519
GI



I

AB Dialkyl urea compds. represented by general formula R3R4NC(:Z)NR5(CH2)nCHR1(CH2)mCO-XR2 [R1, R2 = hydrogen, C1-6 alkyl, C1-6 alkenyl, (un)substituted substituted aryl, alkylaryl, substituted alkylaryl, carbocyclic ring, or heterocyclic ring, and combinations thereof, wherein the combinations are fused or covalently linked and the substituents are selected from the group consisting of halogen, haloalkyl, hydroxy, aryloxy, benzyloxy, alkoxy, haloalkoxy, amino, monoalkylamino, dialkylamino, acyloxy, acyl, alkyl and aryl; R3 = a

2,5 disubstituted aryl; R4, R5 = hydrogen, C1-6 alkyl, or taken together form a ring selected from the group consisting of saturated or unsatd. five-member rings, saturated or unsatd. six-member rings and saturated or unsatd. seven-member rings; Z, X = NH, O, S, or NR, wherein R = C1-6 lower alkyl; n, m = 0 to 6] are prepared These compds. are useful in the treatment of bone-related disorders which are associated with bone resorption and are selected from the group consisting of osteoporosis, Paget's disease, hyperparathyroidism, osteomalacia, periodontal applications (bone loss), hypercalcemia of malignancy and hypercalcemia of infancy. These compds. also provide **analgesic** effect for relief from bone **pain** and are also useful for treating conditions associated with inhibiting gastric secretion. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity. Thus,

PhNHCO-Leu-NHMe was prepared by the solid phase method which involved condensation of Boc-Leu-OH to a p-methylbenzhydrylamine (MBHA) resin, Boc-deprotection with CF3CO2H, Nα-tritylation by trityl chloride, N-methylation, removal of trityl group, reaction with Ph isocyanate, and resin cleavage. 23 Other N-phenylcarbamoyl-amino acid amides were also prepared The title compound N-phenylcarbamoyl-L-tryptophan I, at 25 μg/mL in vitro exhibited 80.63% maximum induction of luciferase in human calcitonin receptor-pos. and receptor-neg. BHK-570 (Baby Hamster Kidney) cell lines.

IT **232603-27-9P 232603-30-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(phenylcarbamoyl)-amino acid amides as calcitonin mimetics for treating bone resorption-related disorders)

RN 232603-27-9 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-N,1-diethyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232603-30-4 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-N,1-di-2-propenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:70361 CAPLUS
DOCUMENT NUMBER: 126:171893
TITLE: Preparation of tryptophan derivatives as tachykinin antagonists
INVENTOR(S): Horwell, David C.; Howson, William; Pritchard, Martyn C.; Roberts, Edward; Rees, David C.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 54 pp., Cont.-in-part of U.S. Ser. No. 97, 264, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5594022	A	19970114	US 1994-344064	19941129
EP 1000930	A2	20000517	EP 2000-102502	19930812
EP 1000930	A3	20031029		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
ES 2153841	T3	20010316	ES 1993-919974	19930812
PT 655055	T	20010330	PT 1993-919974	19930812
US 5716979	A	19980210	US 1996-727067	19961008
US 5856354	A	19990105	US 1997-953037	19971017
US 5981755	A	19991109	US 1998-168512	19981008

PRIORITY APPLN. INFO.:	US 1992-930252	B2	19920813
	US 1993-97264	B2	19930723
	EP 1993-919974	A3	19930812
	US 1994-344064	A3	19941129
	US 1996-727067	A3	19961008
	US 1997-953037	A3	19971017

OTHER SOURCE(S): MARPAT 126:171893
GI



I



II

AB The invention concerns tachykinin antagonists I [R, R6, R8 = independently Ph, pyridine, thiophene, furan, naphthalene, indole, benzofuran, or benzothiophene optionally substituted with 1-3 alkyl, OH, alkoxy, NO2, halo, NH2, CF3, C1-8 straight alkyl, C3-8 branched alkyl, C5-8 cycloalkyl, heterocycloalkyl; R, R2 = independently H, C1-4 alkyl; R and R2 can also form a ring; R3 = H, (CH2)mR13; Y = COR4, CO2, COCH2, CH2O, CH2NH, CH:CH, CH2CH2, CH(OH)CH2, heterocyclic residue; R4, R11 = independently H, C1-3 alkyl; R5, R7 = independently H, C1-4 alkyl; R13 = H, CN, NH2, NMe2, NHAc; m = 1-6; n = 1-2; q = 0, 1], nonpeptides which have utility in treating disorders mediated by tachykinins, such as respiratory, inflammatory, gastrointestinal, ophthalmic and vascular disorders, allergies, **pain**, diseases of the central nervous system, and migraine. Methods of preparing compds. I and novel intermediates are also included. The compds. I are expected to be especially useful in asthma and rheumatoid arthritis. Thus, treatment of α-methyltryptophanyl 1-phenethylamide (preparation given) with 2-benzofuranylmethyl 4-nitrophenyl carbonate (preparation given) gave 56% tryptophan amide II. II exhibited IC50 = 9 nm in an in vitro neurokinin 1 (NK1) receptor binding assay, while related derivs. showed IC50 = 19 to >10,000 nM. II and related compds. were also active in vivo as NK1 receptor antagonists (ID50 = 2.8 to 0.0024 mg/kg IV).

IT **159672-33-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tryptophan derivs. as tachykinin antagonists)

RN 159672-33-0 CAPLUS

CN 1H-Indole-3-propanamide, α-methyl-N-(1-phenylethyl)-α-[[[(phenylmethyl)amino]carbonyl]amino]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1993:517105 CAPLUS
DOCUMENT NUMBER: 119:117105
TITLE: Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
INVENTOR(S): Baker, Raymond; MacLeod, Angus Murray; Merchant, Kevin John; Swain, Christopher John
PATENT ASSIGNEE(S): Merck Sharp and Dohme Ltd., UK
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9301169	A2	19930121	WO 1992-GB1214	19920703
WO 9301169	A3	19931111		
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2110514	AA	19930121	CA 1992-2110514	19920703
AU 9222440	A1	19930211	AU 1992-22440	19920703
AU 664188	B2	19951109		
EP 593557	A1	19940427	EP 1992-914055	19920703
EP 593557	B1	19960131		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
EP 593559	A1	19940427	EP 1992-914089	19920703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06509332	T2	19941020	JP 1992-502085	19920703
US 5472978	A	19951205	US 1993-162096	19931210
US 5629347	A	19970513	US 1993-170190	19931222

PRIORITY APPLN. INFO.:			
GB 1991-14550	A	19910705	
GB 1991-14886	A	19910710	
GB 1991-14888	A	19910710	
GB 1992-1881	A	19920129	
GB 1991-14554	A	19910705	
GB 1992-5294	A	19920311	
WO 1992-GB1213	A	19920703	

WO 1992-GB1214 W 19920703

OTHER SOURCE(S): MARPAT 119:117105
GI



I

AB A series of α-(aminomethyl)heteroarylamines is claimed; exceptions to the claims are cited. The use of these compds. as inflammation inhibitors, analgesics, for the treatment of migraine and for the treatment of postherpetic neuralgia is claimed. Thus, 3,5-dimethylbenzyl bromide was added to a mixture of N-α-BOC-L-tryptophan, cesium carbonate and water/MeOH to give 3,5-dimethylbenzyl 2-[(1,1-dimethylethoxycarbonyl)amino]-3-(3-indolyl)propionate (I). I had in vitro activity as substance P antagonist (IC50 = 110 nmol/L).

IT **148452-11-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as **analgesic** and inflammation inhibitor (substance P antagonist))

RN 148452-11-3 CAPLUS

CN 1H-Indole-3-propanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-α-[[(phenylamino)carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:484251 CAPLUS

DOCUMENT NUMBER: 117:84251

TITLE: Cholecystokinin antagonists, their preparation and therapeutic use

INVENTOR(S): Horwell, David Christopher; Kleinschroth, Juergen; Rees, David Charles; Richardson, Reginald Stewart; Roark, William Howard; Roberts, Edward; Roth, Bruce David; Trivedi, Bharat Kalidas; Holmes, Ann; Padia, Janak Khimchand

PATENT ASSIGNEE(S): Warner-Lambert Co., USA

SOURCE: PCT Int. Appl., 211 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9204045	A1	19920319	WO 1991-US6180		19910829
W: AU, CA, FI, JP, KR, NO					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE					
AU 9187492	A1	19920330	AU 1991-87492		19910829
AU 651390	B2	19940721			
EP 547178	A1	19930623	EP 1991-918880		19910829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
JP 06502627	T2	19940324	JP 1991-517185		19910829
ZA 9106922	A	19930301	ZA 1991-6922		19910830
NO 9300709	A	19930415	NO 1993-709		19930226
NO 312298	B1	20020422			
PRIORITY APPLN. INFO.:			US 1990-576628	A	19900831
			US 1991-726655	A	19910712
			WO 1991-US6180	A	19910829

OTHER SOURCE(S): MARPAT 117:84251

AB Cholecystokinin antagonists (Markush included) are provided for treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, psychotic behavior, anxiety, ulcers, drug withdrawal, and panic. Preparation of the antagonists and intermediates is included; 38 specific compds. are claimed. In receptor binding studies, tricyclo[3.3.1.13,7]dec-2-yl[1-((2-hydroxy-2-phenylethyl)amino)-3-(1H-indol-3-yl)-2-methylprop-2-yl]carbamate had an inhibition constant of 220 nM. Inhibition consts. for 29 other compds. are tabulated.

IT **142627-75-6P 142627-76-7P**
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, for cholecystokinin antagonist)

RN 142627-75-6 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-α-methyl-, [4S-[4α,5α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142627-76-7 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-α-methyl-, [4S-[4α,5α(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142627-61-0P 142627-64-3P 142627-77-8P 142697-57-2P 142697-58-3P**
RL: PREP (Preparation)
(preparation of, for cholecystokinin antagonist)
RN 142627-61-0 CAPLUS
CN 1H-Indole-3-propanamide, N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-α-methyl-α-[[[[(1-phenylcyclopentyl)methyl]amino]carbonyl]amino]-, [4S-[4α,5α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142627-64-3 CAPLUS
CN 1H-Indole-3-propanamide, N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-α-methyl-α-[[[[(1-phenylcyclopentyl)methyl]amino]carbonyl]amino]-, [4S-[4α,5α(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142627-77-8 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-α-methyl-, [1S-[1R*(R*),2R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142697-57-2 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-α-methyl-, [1S-[1R*(S*),2R*]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142697-58-3 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-α-methyl- (9CI) (CA INDEX NAME)



FILE 'REGISTRY' ENTERED AT 15:30:05 ON 11 OCT 2005
L7 51 SEA FILE=REGISTRY ABB=ON PLU=ON (204067-01-6/BI OR
142627-61-0/BI OR 142627-64-3/BI OR 142627-75-6/BI OR
142627-76-7/BI OR 142627-77-8/BI OR 142697-57-2/BI OR
142697-58-3/BI OR 148452-11-3/BI OR 159672-33-0/BI OR
204066-72-8/BI OR 204066-73-9/BI OR 204066-75-1/BI OR
204066-76-2/BI OR 204066-78-4/BI OR 204066-79-5/BI OR
204066-80-8/BI OR 204066-82-0/BI OR 204066-83-1/BI OR
204066-84-2/BI OR 204066-86-4/BI OR 204066-87-5/BI OR
204066-93-3/BI OR 204066-95-5/BI OR 204067-38-9/BI OR
232603-27-9/BI OR 232603-30-4/BI OR 428864-38-4/BI OR
428864-39-5/BI OR 428864-40-8/BI OR 428864-41-9/BI OR
428864-42-0/BI OR 428864-43-1/BI OR 428864-44-2/BI OR
428864-45-3/BI OR 428864-46-4/BI OR 428864-47-5/BI OR
428864-48-6/BI OR 428864-49-7/BI OR 428864-50-0/BI OR
428864-51-1/BI OR 428864-52-2/BI OR 428864-53-3/BI OR
428864-54-4/BI OR 428864-55-5/BI OR 428864-56-6/BI OR
428864-57-7/BI OR 428864-59-9/BI OR 758698-57-6/BI OR
758698-59-8/BI OR 851968-37-1/BI)

FILE 'CAOLD' ENTERED AT 15:30:17 ON 11 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L8 0 L7

FILE 'USPATFULL' ENTERED AT 15:30:24 ON 11 OCT 2005

Searcher : Shears 571-272-2528

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Oct 2005 (20051006/PD)
FILE LAST UPDATED: 6 Oct 2005 (20051006/ED)
HIGHEST GRANTED PATENT NUMBER: US6952836
HIGHEST APPLICATION PUBLICATION NUMBER: US2005223461
CA INDEXING IS CURRENT THROUGH 6 Oct 2005 (20051006/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Oct 2005 (20051006/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

L9 14 L7

L9 ANSWER 1 OF 14 USPATFULL on STN

ACCESSION NUMBER:	2005:138595 USPATFULL
TITLE:	GlyT2 modulators
INVENTOR(S):	Barclay, Tristin K., Denver, CO, UNITED STATES Santillan, Alejandro JR., San Diego, CA, UNITED STATES Tang, Liu Y., San Diego, CA, UNITED STATES Venkatesan, Hariharan, San Diego, CA, UNITED STATES Wolin, Ronald L., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005119245	A1	20050602	
APPLICATION INFO.:	US 2004-976067	A1	20041028	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-515949P	20031030	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
LINE COUNT:	5365

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Certain α-, β-, and γ-amino acid derivatives are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2002:301556 USPATFULL

TITLE: Treatment of sexual dysfunction

INVENTOR(S): Gonzalez, Maria Isabel, Cambridge, UNITED KINGDOM
Higginbottom, Michael, Cambridge, UNITED KINGDOM
Stock, Herman Thijs, Wijchen, NETHERLANDS
Pritchard, Martyn Clive, Huntingdon, UNITED KINGDOM
Pinnock, Robert Denham, Cambridgshire, UNITED KINGDOM
Van Der Graaf, Pieter Hadewijn, Kent, UNITED KINGDOM
Naylor, Alisdair Mark, Kent, UNITED KINGDOM
Wayman, Christopher Peter, Kent, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002169101	A1	20021114
APPLICATION INFO.:	US 2001-999284	A1	20011115 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-759777, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-700165, filed on 9 Nov 2000, PENDING A 371 of International Ser. No. WO 2000-GB1787, filed on 10 May 2000, UNKNOWN

	NUMBER	DATE
PRIORITY. INFORMATION:	GB 2001-9910	20010423
	GB 2001-11037	20010504
	US 1999-133355P	19990510 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: WARNER-LAMBERT COMPANY, 2800 PLYMOUTH ROAD, ANN ARBOR, MI, 48107

NUMBER OF CLAIMS: 67

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 24 Drawing Page(s)

LINE COUNT: 5522

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2002:116302 USPATFULL

TITLE: Dialkyl ureas as calcitonin mimetics

INVENTOR(S): Petrie, Charles R., Woodinville, WA, United States

McKernan, Patricia A., Woodinville, WA, United States
Moore, Emma E., Seattle, WA, United States
Ostresh, John M., Encinitas, CA, United States
Meyer, Jean-Philippe, Holland, PA, United States
Houghten, Richard A., Del Mar, CA, United States
Pinilla, Clemencia, Cardiff, CA, United States
PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391917	B1	20020521
APPLICATION INFO.:	US 2001-838726		20010419 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-410115, filed on 30 Sep 1999, now patented, Pat. No. US 6255351
Division of Ser. No. US 1999-233893, filed on 20 Jan 1999, now patented, Pat. No. US 6221913, issued on 24 Apr 2001

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72987P	19980121 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: O'Sullivan, Peter
LEGAL REPRESENTATIVE: Lingenfelter, Susan E., Walsh, Brian J.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2002:112865 USPATFULL
TITLE: Treatment of sexual dysfunction
INVENTOR(S): Gonzalez, Maria Isabel, Cambridge, UNITED KINGDOM
Pinnock, Robert Denham, Cambridge, UNITED KINGDOM
Pritchard, Martyn Clive, Huntingdon, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058606	A1	20020516
APPLICATION INFO.:	US 2001-759777	A1	20010112 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 700165, PENDING
A 371 of International Ser. No. WO 2000-GB1787, filed on 10 May 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-133355P	19990510 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI, 48105
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 3590
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:102861 USPATFULL
TITLE: Dialkyl ureas as calcitonin mimetics
INVENTOR(S): Petrie, Charles R., Woodinville, WA, United States
McKernan, Patricia A., Woodinville, WA, United States
Moore, Emma E., Seattle, WA, United States
Ostresh, John M., Encinitas, CA, United States
Meyer, Jean-Philippe, Holland, PA, United States
Houghten, Richard A., Del Mar, CA, United States
Pinilla, Clemencia, Cardiff, CA, United States
PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6255351	B1	20010703
APPLICATION INFO.:	US 1999-410115		19990930 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-233893, filed on 20 Jan 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72987P	19980121 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: O'Sullivan, Peter
LEGAL REPRESENTATIVE: Lingenfelter, Susan
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 902
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:59933 USPATFULL
TITLE: Dialkyl ureas as calcitonin mimetics
INVENTOR(S): Petrie, Charles R., Woodinville, WA, United States
McKernan, Patricia A., Woodinville, WA, United States

Moore, Emma E., Seattle, WA, United States
Ostresh, John M., Encinitas, CA, United States
Meyer, Jean-Philippe, Holland, PA, United States
Houghten, Richard A., Del Mar, CA, United States
Pinilla, Clemencia, Cardiff, CA, United States
PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6221913	B1	20010424	
APPLICATION INFO.:	US 1999-233893		19990120	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72987P	19980121 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: O'Sullivan, Peter
LEGAL REPRESENTATIVE: Lingenfelter, Susan E.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 1007
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:29589 USPATFULL
TITLE: Non-peptide bombesin receptor antagonists
INVENTOR(S): Horwell, David Christopher, Cambridge, United Kingdom
Pritchard, Martyn Clive, Cambridgeshire, United Kingdom
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6194437	B1	20010227	
	WO 9807718		19980226	
APPLICATION INFO.:	US 1999-230933		19990203	(9)
	WO 1997-US13871		19970806	
			19990203	PCT 371 date
			19990203	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24323P	19960822 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davis, Zinna Northington
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1
LINE COUNT: 2121
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The compounds of the instant invention are novel compounds of Formula I ##STR1##

or a pharmaceutically acceptable salt thereof wherein Ar is phenyl or pyridyl unsubstituted or substituted. Ar.sup.1 can be independently selected from Ar and can also include pyridyl-N-oxide, indolyl, imidazole, and pyridyl; R.sup.3 can be independently selected from Ar or is hydrogen, hydroxy, NMe.sub.2, N-methyl-pyrrole, imidazole, tetrazole, thiazole (a), (b), (c), or (d), wherein Ar.sup.2 is phenyl or pyridyl. The instant compounds antagonize the bombesin receptors in mammals and are therefore effective in treating and/or preventing depression, psychoses, seasonal affective disorders, cancer, feeding disorders, gastrointestinal disorders, inflammatory bowel disease, sleep disorders, and memory impairment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 14 USPATFULL on STN
ACCESSION NUMBER: 1999:142162 USPATFULL
TITLE: Tachykinin antagonists
INVENTOR(S): Horwell, David Christopher, Foxton, United Kingdom
Howson, William, Weston Colville, United Kingdom
Pritchard, Martyn Clive, St. Ives, United Kingdom
Roberts, Edward, Newmarket, United Kingdom
Rees, David Charles, Glasgow, United Kingdom
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981755		19991109
APPLICATION INFO.:	US 1998-168512		19981008 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-953037, filed on 17 Oct 1993, now patented, Pat. No. US 5856354 which is a division of Ser. No. US 1996-727067, filed on 8 Oct 1996, now patented, Pat. No. US 5716979 which is a division of Ser. No. US 1994-344064, filed on 29 Nov 1994, now patented, Pat. No. US 5594022 And a continuation-in-part of Ser. No. US 1993-97264, filed on 23 Jul 1993, now abandoned And a continuation-in-part of Ser. No. US 1992-930252, filed on 13 Aug 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Oswecki, Jane C.
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 2
LINE COUNT: 3101
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns tachykinin antagonists. The compounds are nonpeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of

the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included. The compounds are expected to be especially useful in asthma and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 14 USPATFULL on STN

ACCESSION NUMBER:	1999:118457 USPATFULL
TITLE:	Non-volatile semiconductor memory device and method of manufacturing non-volatile semiconductor memory device
INVENTOR(S):	Araki, Hitoshi, Yokkaichi, Japan Hatakeyama, Kazuo, Tokyo-to, Japan
PATENT ASSIGNEE(S):	Kabushiki Kaisha Toshiba, Kawasaki, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5959888		19990928	
APPLICATION INFO.:	US 1998-72987		19980506	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-116753	19970507
	JP 1998-75343	19980324

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Nelms, David
ASSISTANT EXAMINER:	Lam, David
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
NUMBER OF CLAIMS:	13
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT:	967

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The non-volatile semiconductor device includes a sub control gate in addition to the conventional structure having a control gate and a floating gate. When writing or erasing is performed, by applying various to the control gate and the sub control gate, the potential of the floating gate which is capacitively connected to the control and sub control gates is determined. Accordingly, the floating gate voltage is maintained at lower control voltage compared to conventional one by selecting larger coupling ratio. The sub control gate covering a part where charge concentration apt to occur avoids charge concentration and deterioration of the tunnel oxide film.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 14 USPATFULL on STN

ACCESSION NUMBER:	1999:1685 USPATFULL
TITLE:	Tachykinin antagonists
INVENTOR(S):	Horwell, David Christopher, Foxton, England Howson, William, Weston Colville, England Pritchard, Martyn Clive, St. Ives, England Roberts, Edward, Wood Ditton, England Rees, David Charles, Glasgow, Scotland
PATENT ASSIGNEE(S):	Warner-Lambert Company, Morris Plains, NJ, United

States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5856354		19990105
APPLICATION INFO.:	US 1997-953037		19971017 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-727067, filed on 8 Oct 1996, now patented, Pat. No. US 5716979 which is a division of Ser. No. US 1994-344064, filed on 29 Nov 1994, now patented, Pat. No. US 5594022 And a continuation-in-part of Ser. No. US 1993-97264, filed on 23 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-930252, filed on 13 Aug 1992, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Oswecki, Jane C.
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 3351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns tachykinin antagonists. The compounds are neopeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included. The compounds are expected to be especially useful in asthma and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 14 USPATFULL on STN
ACCESSION NUMBER: 1998:154250 USPATFULL
TITLE: Cholecystokinin antagonists, their preparation and therapeutic use
INVENTOR(S): Horwell, David Christopher, Foxton, England
Roberts, Edward, New Market, England
Holmes, Ann, Dexter, MI, United States
Padia, Janak Khimchand, Ann Arbor, MI, United States
Roark, William Howard, Ann Arbor, MI, United States
Roth, Bruce David, Ann Arbor, MI, United States
Trivedi, Bharat Kalidas, Farmington Hills, MI, United States
Kleinschroth, Jurgen, Denzlingen, Germany, Federal Republic of
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5846942		19981208
APPLICATION INFO.:	US 1996-709316		19960909 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-41647, filed on 1 Apr 1993, now patented, Pat. No. US 5593967 which is a continuation-in-part of Ser. No. US 1992-839647,

filed on 21 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726655, filed on 12 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-576628, filed on 31 Aug 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Borin, Michael
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 4737
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment with use of nicotine, diazepam, alcohol, cocaine, coffee, or opioids. The compounds of the invention are also useful in treating and/or preventing panic. Also disclosed are pharmaceutical compositions and methods of treatment using the antagonists as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 14 USPATFULL on STN
ACCESSION NUMBER: 1998:14826 USPATFULL
TITLE: Tachykinin antagonists
INVENTOR(S): Horwell, David Christopher, Foxton, England
Howson, William, Weston Colville, England
Pritchard, Martyn Clive, St. Ives, England
Roberts, Edward, Wood Ditton, England
Rees, David Charles, Glasgow, Scotland
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5716979		19980210
APPLICATION INFO.:	US 1996-727067		19961008 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-344064, filed on 29 Nov 1994, now patented, Pat. No. US 5594022 And a continuation-in-part of Ser. No. US 1993-97264, filed on 23 Jul 1993, now abandoned And a continuation-in-part of Ser. No. US 1992-930252, filed on 13 Aug 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Oswecki, Jane C.
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 3367

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns tachykinin antagonists. The compounds are nonpeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included.

The compounds are expected to be especially useful in asthma and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 14 USPATFULL on STN

ACCESSION NUMBER:	97:3869 USPATFULL
TITLE:	Tachykinin antagonists
INVENTOR(S):	Horwell, David C., Foxton, England Howson, William, Weston Colville, England Pritchard, Martyn C., St. Ives, England Roberts, Edward, Wood Ditton, England Rees, David C., Glasgow, Scotland
PATENT ASSIGNEE(S):	Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5594022		19970114
APPLICATION INFO.:	US 1994-344064		19941129 (8)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-97264, filed on 23 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-930252, filed on 13 Aug 1992, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Springer, David B.
LEGAL REPRESENTATIVE:	Anderson, Elizabeth M.
NUMBER OF CLAIMS:	51
EXEMPLARY CLAIM:	1
LINE COUNT:	3534

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns tachykinin antagonists. The compounds are nonpeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included.

The compounds are expected to be especially useful in asthma and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 14 USPATFULL on STN

ACCESSION NUMBER:	97:3815 USPATFULL
TITLE:	Cholecystokinin antagonists, their preparation and therapeutic use
INVENTOR(S):	Horwell, David C., Cambridge, England Roberts, Edward, Wood Ditton, England Holmes, Ann, Dexter, MI, United States

Padia, Janak K., Ann Arbor, MI, United States
Roark, William H., Ann Arbor, MI, United States
Roth, Bruce D., Ann Arbor, MI, United States
Trivedi, Bharat K., Farmington Hills, MI, United States
Kleinschroth, Jurgen, Denzlingen, Germany, Federal Republic of
Rees, David C., Cambridge, England
Richardson, Reginald S., Haverhill, England
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5593967		19970114
APPLICATION INFO.:	US 1993-41647		19930401 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-839647, filed on 21 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726655, filed on 12 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-576628, filed on 31 Aug 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weimar, Elizabeth C.
ASSISTANT EXAMINER: Marshall, Sg
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 4574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment with use of nicotine, diazepam, alcohol, cocaine, coffee, or opioids. The compounds of the invention are also useful in treating and/or preventing panic. Also disclosed are pharmaceutical compositions and methods of treatment using the antagonists as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FILE 'MEDLINE' ENTERED AT 15:30:32 ON 11 OCT 2005

FILE 'BIOSIS' ENTERED AT 15:30:32 ON 11 OCT 2005

FILE 'EMBASE' ENTERED AT 15:30:32 ON 11 OCT 2005

L10 9 L7

=> dup rem l10
PROCESSING COMPLETED FOR L10

L11 9 DUP REM L10 (0 DUPLICATES REMOVED)

L11 ANSWER 1 OF 9 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:499337 BIOSIS
DOCUMENT NUMBER: PREV200300501538
TITLE: Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells.
AUTHOR(S): Moody, Terry W. [Reprint Author]; Leyton, Julius; Garcia-Marin, Luis; Jensen, Robert T.
CORPORATE SOURCE: Office of the Director, CCR, NCI, 31 Center Drive, Building 31, Room 3A34, Bethesda, MD, 20892, USA moodyt@mail.nih.gov
SOURCE: European Journal of Pharmacology, (1 August 2003) Vol. 474, No. 1, pp. 21-29. print.
ISSN: 0014-2999 (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 29 Oct 2003
Last Updated on STN: 29 Oct 2003

AB The ability of nonpeptide antagonists to interact with gastrin releasing peptide receptors on lung cancer cells was investigated. PD176252 (3-(1H-Indol-3-yl)-N-(1-(5-methoxy-pyridin-2-yl)-cyclobexylmethyl)-2-methyl-2-(3-(4-nitro-phenyl)-ureido)-propionamide) and PD168368 (3-(1H-Indol-3-yl)-2-methyl-2-(3(4-nitro-phenyl)-ureido)-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide) inhibited specific 125I-gastrin releasing peptide binding to NCI-H1299 cells with IC50 values of 20 and 1500 nM, respectively. Similar binding results were obtained using NCI-H157, H345 and N592 human lung cancer cells. PD176252 inhibited the ability of 1 nM bombesin to cause elevation of cytosolic calcium in Fura-2 loaded NCI-H345 or H1299 cells, whereas it had no effect on basal cytosolic calcium. PD176252 antagonized the ability of 10 nM bombesin to cause elevation of c-fos mRNA in NCI-H1299 cells. Also, PD176252 inhibited the ability of 100 nM bombesin to cause tyrosine phosphorylation of focal adhesion kinase in NCI-H1299 cells. Using a (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) assay, PD176252 was more potent than PD168368 at inhibiting NCI-H1299 proliferation. Also, 1 muM PD176252 significantly inhibited lung cancer colony number in vitro. PD176252 in a dose-dependent manner inhibited NCI-H1299 xenograft growth in nude mice in vivo. These results indicate that PD176252 is a gastrin releasing peptide receptor antagonist, which inhibits the proliferation of lung cancer cells.

L11 ANSWER 2 OF 9 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:283552 BIOSIS
DOCUMENT NUMBER: PREV200100283552
TITLE: Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368.
AUTHOR(S): Tokita, Kenji; Hocart, Simon J.; Katsuno, Tatsuro; Mantey, Samuel A.; Coy, David H.; Jensen, Robert T. [Reprint author]
CORPORATE SOURCE: Digestive Diseases Branch, NIDDK, National Institutes of Health, 10 Center Dr., Bldg. 10, Rm. 9C-103, Bethesda, MD, 20892-1804, USA robertj@bdg10.niddk.nih.gov

Searcher : Shears 571-272-2528

SOURCE: Journal of Biological Chemistry, (January 5, 2001) Vol. 276, No. 1, pp. 495-504. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 13 Jun 2001
Last Updated on STN: 19 Feb 2002

AB Peptoid antagonists are increasingly being described for G protein-coupled receptors; however, little is known about the molecular basis of their binding. Recently, the peptoid PD168368 was found to be a potent selective neuromedin B receptor (NMBR) antagonist. To investigate the molecular basis for its selectivity for the NMBR over the closely related receptor for gastrin-releasing peptide (GRPR), we used a chimeric receptor approach and a site-directed mutagenesis approach. Mutated receptors were transiently expressed in Balb 3T3. The extracellular domains of the NMBR were not important for the selectivity of PD168368. However, substitution of the 5th upper transmembrane domain (uTM5) of the NMBR by the comparable GRPR domains decreased the affinity 16-fold. When the reverse study was performed by substituting the uTM5 of NMBR into the GRPR, a 9-fold increase in affinity occurred. Each of the 4 amino acids that differed between NMBR and GRPR in the uTM5 region were exchanged, but only the substitution of Phe220 for Tyr in the NMBR caused a decrease in affinity. When the reverse study was performed to attempt to demonstrate a gain of affinity in the GRPR, the substitution of Tyr219 for Phe caused an increase in affinity. These results suggest that the hydroxyl group of Tyr220 in uTM5 of NMBR plays a critical role for high selectivity of PD168368 for NMBR over GRPR. Receptor and ligand modeling suggests that the hydroxyl of the Tyr220 interacts with nitrophenyl group of PD168368 likely primarily by hydrogen bonding. This result shows the selectivity of the peptoid PD168368, similar to that reported for numerous non-peptide analogues with other G protein-coupled receptors, is primarily dependent on interaction with transmembrane amino acids.

L11 ANSWER 3 OF 9 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:38566 BIOSIS
DOCUMENT NUMBER: PREV200100038566
TITLE: Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells.
AUTHOR(S): Moody, Terry W. [Reprint author]; Jensen, Robert T.; Garcia, Luis; Leyton, Julius
CORPORATE SOURCE: Cell and Cancer Biology Department, Medicine Branch, National Cancer Institute, 9610 Medical Center Drive, Bldg. KWC, Rm. 300, Rockville, MD, 20850, USA
moodyt@bprb.nci.nih.gov
SOURCE: European Journal of Pharmacology, (8 December, 2000) Vol. 409, No. 2, pp. 133-142. print.
CODEN: EJPHAZ. ISSN: 0014-2999.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 17 Jan 2001
Last Updated on STN: 15 Feb 2002

AB The ability of nonpeptide antagonists to interact with neuromedin B receptors on C6 cells was investigated. 2-(3-(2,6-Diisopropylphenyl)-ureido)3-(1H-indol-3-yl)-2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-proprionate (PD165929), 3-(1H-indol-3-yl)-2-methyl-2-(3(4-nitro-phenyl)-ureido)-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide

(PD168368) and 3-(1H-indol-3-yl)-N-(1-(5-methoxy-pyridin-2-yl)-cyclohexylmethyl)-2-methyl-2-(3-(4-mitro-phenyl)-ureido)-propionamide (PD176252) inhibited (125I-Tyr0)neuromedin B binding with IC50 values of 2000, 40 and 50 nM, respectively. Because neuromedin B is a G-protein coupled serpentine receptor, the effects of neuromedin B antagonists on second messenger production and proliferation were investigated. PD168368 inhibited the ability of 10 nM neuromedin B to cause elevation of cytosolic Ca2+, whereas it had no effect on basal cytosolic Ca2+. PD168368 inhibited the ability of 100 nM neuromedin B to cause elevation of c-fos mRNA. Also, PD168368 in a dose-dependent manner inhibited the ability of 100 nM neuromedin B to cause phosphorylation of focal adhesion kinase. Using a (3-(4,5 dimethylthiazol-2-yl)-2.5-diphenyl-2H-tetrazolium bromide) assay, the order of antagonist potency to inhibit C6 proliferation was PD168368 = PD176252 > PD165929. Also, 1 muM PD168368 and PD176252 significantly inhibited colony number using a proliferation assay in vitro. PD168368 significantly inhibited C6 xenograft growth in nude mice in vivo. These results indicate that PD168368 is a C6 cell neuromedin B receptor antagonist, which inhibits proliferation.

L11 ANSWER 4 OF 9 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 1999:439452 BIOSIS
DOCUMENT NUMBER: PREV199900439452
TITLE: Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
AUTHOR(S): Ryan, Richard R.; Katsuno, Tatsuro; Mantey, Samuel A.; Pradhan, Tapas K.; Weber, H. Christian; Coy, David H.; Battey, James F.; Jensen, Robert T. [Reprint author]
CORPORATE SOURCE: Digestive Diseases Branch, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 10 Center Dr., Bldg. 10, Room 9C-103, Bethesda, MD, 20892-1804, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics, (Sept., 1999) Vol. 290, No. 3, pp. 1202-1211. print. CODEN: JPETAB. ISSN: 0022-3565.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 18 Oct 1999
Last Updated on STN: 18 Oct 1999

AB The mammalian peptide neuromedin B (NMB) and its receptor are expressed in a variety of tissues; however, little is definitively established about its physiological actions because of the lack of potent, specific antagonists. Recently, the peptoid PD 168368 was found to be a potent human NMB receptor antagonist. Because it had been shown previously that either synthetic analogs of bombesin (Bn) or other receptor peptoid or receptor antagonists function as an antagonist or agonist depends on animal species and receptor subtype studied, we investigated the pharmacological properties of PD 168368 compared with all currently known Bn receptor subtypes (NMB receptor, gastrin-releasing peptide receptor, Bn receptor subtype 3, and Bn receptor subtype 4) from human, mouse, rat, and frog. In binding studies, PD 168368 had similar high affinities (Ki = 15-45 nM) for NMB receptors from each species examined, 30- to 60-fold lower affinity for gastrin-releasing peptide receptors, and >300-fold lower affinity for Bn receptor subtype 3 or 4. It inhibited NMB binding in a competitive manner. PD 168368 alone did not stimulate increases in either intracellular calcium concentration or (3H)inositol phosphates in any of the cells studied but inhibited NMB-induced responses with

equivalent potencies in cells containing NMB receptors. PD 168368 was only minimally soluble in water. When hydroxypropyl-beta-cyclodextrin rather than dimethyl sulfoxide was used as the vehicle, both the affinity and the antagonist potency of PD 168368 were significantly greater. The results demonstrate that PD 168368 is a potent, competitive, and selective antagonist at NMB receptors, with a similar pharmacology across animal species. PD 168368 should prove useful for delineating the biological role of NMB and selectively blocking NMB signaling in bioassays and as a lead for the development of more selective nonpeptide antagonists for the NMB receptor.

L11 ANSWER 5 OF 9 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:336345 BIOSIS
DOCUMENT NUMBER: PREV199900336345
TITLE: The peptoid PD 168368 is a potent antagonist on human and rodent neuromedin B receptors.
AUTHOR(S): Ryan, R. [Reprint author]; Mantey, S. A. [Reprint author]; Pradhan, T. K. [Reprint author]; Coy, D. H. [Reprint author]; Battey, J. F. [Reprint author]; Jensen, R. T.
CORPORATE SOURCE: NIH, Bethesda, MD, USA
SOURCE: Gastroenterology, (April, 1999) Vol. 116, No. 4 PART 2, pp. A1072. print.
Meeting Info.: Digestive Disease Week and the 100th Annual Meeting of the American Gastroenterological Association. Orlando, Florida, USA. May 16-19, 1999. American Gastroenterological Association.
CODEN: GASTAB. ISSN: 0016-5085.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 24 Aug 1999
Last Updated on STN: 24 Aug 1999

L11 ANSWER 6 OF 9 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:291060 BIOSIS
DOCUMENT NUMBER: PREV199900291060
TITLE: Ability of a newly described, non-peptide neuromedin B receptor antagonist to interact with mammalian bombesin receptors.
AUTHOR(S): Mantey, S. A. [Reprint author]; Ryan, R. R. [Reprint author]; Pradhan, T. K. [Reprint author]; Coy, D. H. [Reprint author]; Battey, J. F. [Reprint author]; Jensen, R. T. [Reprint author]
CORPORATE SOURCE: NIH, Bethesda, MD, USA
SOURCE: Gastroenterology, (April, 1999) Vol. 116, No. 4 PART 2, pp. A625. print.
Meeting Info.: Digestive Disease Week and the 100th Annual Meeting of the American Gastroenterological Association. Orlando, Florida, USA. May 16-19, 1999. American Gastroenterological Association.
CODEN: GASTAB. ISSN: 0016-5085.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 5 Aug 1999
Last Updated on STN: 5 Aug 1999

Searcher : Shears 571-272-2528

L11 ANSWER 7 OF 9 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:167407 BIOSIS
DOCUMENT NUMBER: PREV199900167407
TITLE: Comparative pharmacology of PD 168368, a non-peptide neuromedin B antagonist.
AUTHOR(S): Ryan, R. R.; Mantey, S. A.; Pradhan, T. K.; Battey, J. F.; Jensen, R. T.
CORPORATE SOURCE: National Inst. Health, Bethesda, MD 20892, USA
SOURCE: FASEB Journal, (March 12, 1999) Vol. 13, No. 4 PART 1, pp. A466. print.
Meeting Info.: Annual Meeting of the Professional Research Scientists for Experimental Biology 99. Washington, D.C., USA. April 17-21, 1999.
CODEN: FAJOEC. ISSN: 0892-6638.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Apr 1999
Last Updated on STN: 19 Apr 1999

L11 ANSWER 8 OF 9 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1998:485569 BIOSIS
DOCUMENT NUMBER: PREV199800485569
TITLE: PD 176252: The first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist.
AUTHOR(S): Ashwood, V.; Brownhill, V.; Higginbottom, M.; Horwell, D. C.; Hughes, J.; Lewthwaite, R. A. [Reprint author]; McKnight, A. T.; Pinnock, R. D.; Pritchard, M. C. [Reprint author]; Suman-Chauhan, N.; Webb, C.; Williams, S. C.
CORPORATE SOURCE: Parke-Davis Neurosci. Res. Cent., Cambridge Univ. Forvie Site, Robinson Way, Cambridge CB2 2QB, UK
SOURCE: Bioorganic and Medicinal Chemistry Letters, (Sept. 22, 1998) Vol. 8, No. 18, pp. 2589-2594. print.
CODEN: BMCLE8. ISSN: 0960-894X.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 5 Nov 1998
Last Updated on STN: 5 Nov 1998
AB In this paper we describe the development of a novel series of non-peptide, "balanced" neuromedin-B preferring (BB1)/gastrin-releasing peptide preferring (BB2) receptor ligands as exemplified by PD 176252. PD 176252, which exhibits nanomolar affinity for both the BB1 (Ki=0.15nM) and BB2 (Ki=1.0nM) receptors, has been demonstrated to be a competitive antagonist at these bombesin receptor subtypes.

L11 ANSWER 9 OF 9 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:67120 BIOSIS
DOCUMENT NUMBER: PREV199900067120
TITLE: PD168368 is a neuromedin B receptor antagonist for C6 cells.
AUTHOR(S): Moody, T. W. [Reprint author]
CORPORATE SOURCE: Natl. Cancer Inst., Med. Branch, Cell Cancer Biol. Dep., Rockville, MD 20850, USA
SOURCE: Society for Neuroscience Abstracts, (1998) Vol. 24, No.

1-2, pp. 1090. print.
Meeting Info.: 28th Annual Meeting of the Society for Neuroscience, Part 1. Los Angeles, California, USA. November 7-12, 1998. Society for Neuroscience.
ISSN: 0190-5295.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 16 Feb 1999
Last Updated on STN: 16 Feb 1999

FILE 'CANCERLIT' ENTERED AT 15:47:21 ON 11 OCT 2005

FILE COVERS 1963 TO 15 Nov 2002 (20021115/ED)

On July 28, 2002, CANCERLIT was reloaded. See HELP RLOAD for details.

CANCERLIT thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L12 0 L7

=> fil hom
FILE 'HOME' ENTERED AT 15:47:25 ON 11 OCT 2005

```
=> d que stat l4; d his ful l1-l11
L1              STR
```




```
REP G1=(0-1) C
REP G2=(0-1) CH2
VAR G3=H/AK
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE
L2  (       468)SEA FILE=REGISTRY SSS FUL L1
L3              STR
```




```
REP G1=(0-1) C
REP G2=(0-1) CH2
VAR G3=H/16
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS LOC  AT  16
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M1 N  AT  13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  16

STEREO ATTRIBUTES: NONE
L4          414 SEA FILE=REGISTRY SUB=L2 SSS FUL L3

100.0% PROCESSED     468 ITERATIONS                          414 ANSWERS
SEARCH TIME: 00.00.01

=> d his ful
```

```
     (FILE 'REGISTRY' ENTERED AT 15:21:37 ON 11 OCT 2005)
                DEL HIS Y
                ACT DELAC70016/A
               ---------
L1              STR
L2  (       468)SEA SSS FUL L1
L3              STR
L4           414 SEA SUB=L2 SSS FUL L3
                 ---------

     FILE 'REGISTRY' ENTERED AT 15:27:04 ON 11 OCT 2005
                D QUE STAT

     FILE 'CAPLUS' ENTERED AT 15:27:04 ON 11 OCT 2005
L5             77 SEA ABB=ON  PLU=ON  L4
L6              9 SEA ABB=ON  PLU=ON  L5 AND (PAIN OR PHYSICAL?(3A)SUFFER?
                  OR ANALGESI# OR ANTINOCICEPT? OR ANTI NOCICEPT? OR ACHE#
                  OR ACHING)
                  SEL HIT L6 1-9 RN
                  DEL SEL Y
                  SEL HIT L6 1-9 RN
                  D L6 1-9 IBIB ABS HITSTR

     FILE 'REGISTRY' ENTERED AT 15:30:05 ON 11 OCT 2005
L7             51 SEA ABB=ON  PLU=ON  (204067-01-6/BI OR 142627-61-0/BI OR
                  142627-64-3/BI OR 142627-75-6/BI OR 142627-76-7/BI OR
                  142627-77-8/BI OR 142697-57-2/BI OR 142697-58-3/BI OR
                  148452-11-3/BI OR 159672-33-0/BI OR 204066-72-8/BI OR
                  204066-73-9/BI OR 204066-75-1/BI OR 204066-76-2/BI OR
                  204066-78-4/BI OR 204066-79-5/BI OR 204066-80-8/BI OR
                  204066-82-0/BI OR 204066-83-1/BI OR 204066-84-2/BI OR
                  204066-86-4/BI OR 204066-87-5/BI OR 204066-93-3/BI OR
                  204066-95-5/BI OR 204067-38-9/BI OR 232603-27-9/BI OR
                  232603-30-4/BI OR 428864-38-4/BI OR 428864-39-5/BI OR
                  428864-40-8/BI OR 428864-41-9/BI OR 428864-42-0/BI OR
                  428864-43-1/BI OR 428864-44-2/BI OR 428864-45-3/BI OR
                  428864-46-4/BI OR 428864-47-5/BI OR 428864-48-6/BI OR
                  428864-49-7/BI OR 428864-50-0/BI OR 428864-51-1/BI OR
                  428864-52-2/BI OR 428864-53-3/BI OR 428864-54-4/BI OR
                  428864-55-5/BI OR 428864-56-6/BI OR 428864-57-7/BI OR
                  428864-59-9/BI OR 758698-57-6/BI OR 758698-59-8/BI OR
                  851968-37-1/BI)
                  D QUE

     FILE 'CAOLD' ENTERED AT 15:30:17 ON 11 OCT 2005
L8              0 SEA ABB=ON  PLU=ON  L7

     FILE 'USPATFULL' ENTERED AT 15:30:24 ON 11 OCT 2005
L9             14 SEA ABB=ON  PLU=ON  L7
                  D 1-14 IBIB ABS

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 15:30:32 ON 11 OCT 2005
L10             9 SEA ABB=ON  PLU=ON  L7
L11             9 DUP REM L10 (0 DUPLICATES REMOVED)
                  D 1-9 IBIB ABS

     FILE 'MARPAT' ENTERED AT 15:30:48 ON 11 OCT 2005
L*** DEL          STR L3
L*** DEL          STR L12
```

```
L*** DEL     16 SEARCH L*** SSS SAM
L*** DEL        STR L***
L*** DEL     14 SEARCH L*** SSS SAM
L*** DEL        STR L***
L*** DEL     14 SEARCH L*** SSS SAM
L*** DEL      0 SEARCH L*** CSS SAM

     FILE 'HOME' ENTERED AT 15:42:22 ON 11 OCT 2005
               D QUE STAT L4
               D COST

     FILE 'CANCERLIT' ENTERED AT 15:47:21 ON 11 OCT 2005
L12             0 SEA ABB=ON  PLU=ON  L7

     FILE 'HOME' ENTERED AT 15:47:25 ON 11 OCT 2005


     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   10 OCT 2005  HIGHEST RN 864908-12-3
     DICTIONARY FILE UPDATES:  10 OCT 2005  HIGHEST RN 864908-12-3

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMI
     for details.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storin
```

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Oct 2005 VOL 143 ISS 16
FILE LAST UPDATED: 10 Oct 2005 (20051010/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE CAOLD
FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Oct 2005 (20051006/PD)
FILE LAST UPDATED: 6 Oct 2005 (20051006/ED)
HIGHEST GRANTED PATENT NUMBER: US6952836
HIGHEST APPLICATION PUBLICATION NUMBER: US2005223461
CA INDEXING IS CURRENT THROUGH 6 Oct 2005 (20051006/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Oct 2005 (20051006/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

>>> USPAT2 is now available. USPATFULL contains full text of the
>>> original, i.e., the earliest published granted patents or
>>> applications. USPAT2 contains full text of the latest US
>>> publications, starting in 2001, for the inventions covered in
>>> USPATFULL. A USPATFULL record contains not only the original
>>> published document but also a list of any subsequent
>>> publications. The publication number, patent kind code, and
>>> publication date for all the US publications for an invention
>>> are displayed in the PI (Patent Information) field of USPATFULL
>>> records and may be searched in standard search fields, e.g., /PN,
>>> /PK, etc.

>>> USPATFULL and USPAT2 can be accessed and searched together
>>> through the new cluster USPATALL. Type FILE USPATALL to
>>> enter this cluster.
>>>
>>> Use USPATALL when searching terms such as patent assignees,
>>> classifications, or claims, that may potentially change from
>>> the earliest to the latest publication.

This file contains CAS Registry Numbers for easy and accurate

substance identification.

FILE MEDLINE
FILE LAST UPDATED: 8 OCT 2005 (20051008/UP). FILE COVERS 1950 TO DAT

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow promt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 5 October 2005 (20051005/ED)

FILE RELOADED: 19 October 2003.

FILE EMBASE
FILE COVERS 1974 TO 6 Oct 2005 (20051006/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE MARPAT
FILE CONTENT: 1988-PRESENT (VOL 143 ISS 15)(20051007/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6916824 12 JUL 2005
DE 10359831 14 JUL 2005
EP 1550665 06 JUL 2005
JP 2005183717 07 JUL 2005
WO 2005079855 01 SEP 2005

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

FILE HOME

FILE CANCERLIT
FILE COVERS 1963 TO 15 Nov 2002 (20021115/ED)

On July 28, 2002, CANCERLIT was reloaded. See HELP RLOAD for details

CANCERLIT thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

This file contains CAS Registry Numbers for easy and accurate substan identification.

Searcher : Shears 571-272-2528